Etoposide combined with anlotinib and sintilimab successfully achieved long term progression-free survival in platinum-refractory ovarian cancer: A case report
This case demonstrates that the combination of etoposide, anlotinib, and sintilimab can induce sustained CR in platinum-refractory ovarian cancer, achieving remarkable 23.9-month PFS. The synergistic activity of this regimen successfully reversed multidrug resistance and may redefine third-line therapeutic strategies for this challenging population.
Authors
- Ping Lü (ORCID: https://orcid.org/0009-0006-6008-6469)
- Kelei Zhao (ORCID: https://orcid.org/0000-0002-2515-065X)
- Luying Zhang (ORCID: https://orcid.org/0000-0002-1304-4550)
- Min Zhang (ORCID: https://orcid.org/0009-0007-4363-8492)
- Yang Li (ORCID: https://orcid.org/0000-0003-1053-4519)
- Yanting Liu (ORCID: https://orcid.org/0000-0002-9591-3042)
- Chang Qiu (ORCID: https://orcid.org/0000-0002-7701-0130)
- Yuxin Wang
- Xiaohan Yuan
Institutions
- First Affiliated Hospital of Xinxiang Medical University (CN)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1016/j.gore.2025.101999
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00